Gossamer Bio Seralutinib Phase 3 p-Value Clears 0.05, Stock Gains 23.4%
On Feb. 23 Gossamer reported PROSERA Phase 3 seralutinib topline data in PAH, narrowly missing its prespecified primary threshold while achieving a p-value under 0.05. Shares plunged 76% to a 52-week low of $0.33 before rebounding 23.4% to $0.58 as the RSI dropped to 26.3.
1. Phase 3 PROSERA Study Results
On Feb. 23 Gossamer released topline data from its PROSERA Phase 3 study of seralutinib in pulmonary arterial hypertension, narrowly missing the stringent prespecified primary endpoint but still registering a p-value below the traditional 0.05 threshold, indicating statistical drug activity.
2. Stock Performance and Technical Indicators
Following the data release, shares fell about 76% over the past month to a 52-week low of $0.33, then rallied 23.4% to close at $0.58 on Wednesday; the RSI reading of 26.3 underscores the stock’s deeply oversold condition and subsequent snapback.
3. Outlook and Next Steps
Gossamer plans to engage regulators on potential approval pathways and conduct further analyses of secondary and exploratory endpoints, while investors will monitor additional trial readouts and potential partnership discussions that could bolster the company’s PAH pipeline valuation.